Journal
PEPTIDES
Volume 132, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.peptides.2020.170373
Keywords
Mycobacterium tuberculosis; Cationic antibacterial peptides; Macrophage; B1CTcu5
Funding
- Department of Biotechnology [BT/PR8835/NDB/52/61/2007]
- Government of India
Ask authors/readers for more resources
Tuberculosis (TB) is a devastating infectious disease that causes a high rate of mortality. Drugs with new modes of action are needed to overcome this scenario. Cationic antibacterial peptides can serve as a potential alternative to existing TB drugs as they target the entire bacterial membrane for activity, thereby reducing the probability of development of drug resistance. In this study, we report anti-tuberculosis activity of B1CTcu5, a peptide that belongs to brevinin-1 family of antimicrobial peptides. This peptide possesses potent in vitro inhibitory activity against M. tuberculosis at 12.5 mu g/mL but was not active against M. smegmatis. B1CTcu5 successfully eliminated intracellular mycobacteria without inducing cytotoxicity to the human macrophages at the concentrations tested. This peptide can be used as a template to design peptide-based anti-tubercular agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available